MarketCap
Facebook
X
TelegramQuarterly report 2026-Q1
added 05-11-2026
SCYNEXIS Long-Term Debt 2011-2026 | SCYX
Long-term debt is a financial obligation of a company or an individual with a repayment period exceeding one year from the date it arises. In accounting, such obligations are recorded under the "long-term liabilities" section.
Main characteristics:- Term exceeds 12 months
- Can take the form of bonds, bank loans, credit lines, leasing, or loans from affiliated parties
- Repaid through regular payments (interest and/or principal) over several years
- Investment in development
Allows financing of large projects — new factories, production lines, innovative developments — without diverting working capital. - Smoothing of cash flows
A long-term payment schedule facilitates budget planning and reduces short-term financial risks. - Optimization of capital structure
A combination of equity and borrowed capital can reduce the average cost of business financing.
A high level of long-term debt may indicate that a company heavily relies on borrowed funds. This increases risks, especially in conditions of rising interest rates or declining profits. However, a moderate level of debt can signal a sound growth strategy — for example, the company takes a loan to expand its business.
If a company uses borrowed funds effectively (e.g., invests in profitable projects), this can lead to profit growth and, consequently, an increase in stock value. An investor evaluates whether the investments made using debt are paying off.
It is important to monitor whether the company can regularly pay interest and repay the principal. Payment difficulties can lead to reduced dividends, a drop in stock value, and even bankruptcy.
Examples of long-term debt:- Mortgage loans for property purchases
- Corporate bonds issued by a company to raise capital
- Project financing — long-term loans for building or expanding production facilities
- Leasing obligations for equipment or transport
Annual Long-Term Debt SCYNEXIS
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.69 M | 2.18 M | 2.58 M | 2.92 M | 34.4 M | 16.5 M | 11.5 M | 15.1 M | 10.3 M | 14.3 M | - | - | - | 15 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 34.4 M | 1.69 M | 11.5 M |
Quarterly Long-Term Debt SCYNEXIS
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.56 M | 1.82 M | 1.94 M | 2.06 M | 2.18 M | 2.28 M | 2.39 M | 2.49 M | 2.58 M | 2.67 M | 2.76 M | 34.6 M | 2.92 M | 34.2 M | 33.9 M | 33.7 M | 3.2 M | 28.6 M | 28.4 M | 3.22 M | 3.27 M | 3.27 M | 3.27 M | 3.27 M | - | - | - | - | 15.1 M | 15.1 M | 15.1 M | 15.1 M | 10.3 M | 10.3 M | 10.3 M | 10.3 M | 14.3 M | 14.3 M | 14.3 M | 14.3 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 34.6 M | 1.56 M | 11.1 M |
Long-Term Debt of other stocks in the Drug manufacturers industry
| Issuer | Long-Term Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Cumberland Pharmaceuticals
CPIX
|
4.47 M | $ 5.47 | 11.18 % | $ 81.3 M |  USA |
 |
Evoke Pharma
EVOK
|
101 K | - | - | $ 36.6 M | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
27.1 M | - | -0.1 % | $ 2.03 B |  Schweden |
 |
AcelRx Pharmaceuticals
ACRX
|
5.01 M | - | 7.5 % | $ 6.35 M | USA |
 |
DURECT Corporation
DRRX
|
1.12 M | - | - | $ 50.1 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
343 K | - | 0.86 % | $ 117 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
21.8 M | - | - | $ 754 M | USA |
 |
Agile Therapeutics
AGRX
|
1.52 M | - | 10.11 % | $ 58.2 M | USA |
 |
Alimera Sciences
ALIM
|
256 K | - | - | $ 142 M | USA |
 |
Cronos Group
CRON
|
1.17 M | $ 2.63 | -4.01 % | $ 1.01 B |  Canada |
 |
Harrow Health
HROW
|
250 M | $ 31.21 | 1.13 % | $ 1.15 B | USA |
 |
Athenex
ATNX
|
93 K | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
1.12 M | - | - | $ 2.06 B |  France |
 |
Catalent
CTLT
|
4.86 B | - | - | $ 11.5 B | USA |
 |
HEXO Corp.
HEXO
|
29 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Eagle Pharmaceuticals
EGRX
|
56.2 M | - | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
8.15 B | - | - | $ 28.9 M |  Irlanda |
 |
Organogenesis Holdings
ORGO
|
12.8 M | $ 2.41 | -6.95 % | $ 305 M | USA |
 |
Bausch Health Companies
BHC
|
21.9 B | $ 5.42 | -0.55 % | $ 1.98 B | Canada |
 |
Pacira BioSciences
PCRX
|
585 M | $ 22.64 | -3.78 % | $ 1.05 B | USA |
 |
Solid Biosciences
SLDB
|
19.1 M | $ 6.92 | -9.31 % | $ 606 M | USA |
 |
Canopy Growth Corporation
CGC
|
300 M | $ 1.04 | -2.8 % | $ 112 M | Canada |
 |
Tilray
TLRY
|
221 M | $ 5.32 | -3.27 % | $ 3.29 B | Canada |
 |
Aurora Cannabis
ACB
|
37.5 M | $ 3.32 | -0.9 % | $ 182 M | Canada |
 |
Sonoma Pharmaceuticals
SNOA
|
27 K | $ 1.09 | -7.63 % | $ 1.35 M | USA |
 |
Jupiter Wellness
JUPW
|
114 K | - | - | $ 33.6 M | USA |
 |
Lannett Company
LCI
|
615 M | - | 1.15 % | $ 7.11 M | USA |
 |
OrganiGram Holdings
OGI
|
3.34 M | $ 1.07 | -1.83 % | $ 102 M | Canada |
 |
Evolus
EOLS
|
146 M | $ 6.5 | -1.22 % | $ 419 M | USA |
 |
Sundial Growers
SNDL
|
16.2 M | $ 1.43 | -2.05 % | $ 3.37 M | Canada |
 |
Veru
VERU
|
2.36 M | $ 2.11 | 0.96 % | $ 30.9 M | USA |
 |
Emergent BioSolutions
EBS
|
446 M | $ 7.94 | -3.29 % | $ 407 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
5 K | - | - | $ 193 M | Canada |
 |
ProPhase Labs
PRPH
|
2.4 M | - | - | $ 5.07 M | USA |
 |
Radius Health
RDUS
|
315 K | - | - | $ 1.42 B | USA |
 |
cbdMD
YCBD
|
9 | $ 0.77 | -6.44 % | $ 3.1 M | USA |
 |
Assertio Holdings
ASRT
|
39.1 M | $ 23.32 | - | $ 149 M | USA |
 |
PetIQ
PETQ
|
438 M | - | 1.64 % | $ 400 M | USA |
 |
Relmada Therapeutics
RLMD
|
2.66 M | $ 6.9 | -7.01 % | $ 272 M | USA |
 |
Recro Pharma
REPH
|
339 K | - | -4.76 % | $ 65.3 M | USA |
 |
OptiNose
OPTN
|
611 K | - | - | $ 1.08 B | USA |
 |
PLx Pharma
PLXP
|
622 K | - | -27.8 % | $ 2.56 M | USA |
 |
Viatris
VTRS
|
12.5 B | $ 16.48 | -4.52 % | $ 19.2 B | USA |
 |
Zomedica Corp.
ZOM
|
1.47 M | - | -0.21 % | $ 98 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
120 K | - | - | $ 55.5 M | USA |
 |
Rockwell Medical
RMTI
|
8.83 M | $ 0.79 | -0.55 % | $ 28.4 M | USA |
 |
Tricida
TCDA
|
11.3 M | - | - | $ 3.25 M | USA |
 |
China Pharma Holdings
CPHI
|
112 K | $ 1.04 | -16.13 % | $ 4.46 M |  China |
 |
TherapeuticsMD
TXMD
|
5.12 M | $ 2.0 | 0.5 % | $ 23.1 M | USA |